Key result
Host genetic variants, including a ~0.9-Mb inversion polymorphism at 17q21.31 and a new locus at 19q13.33 (including NAPSA), were associated with severe COVID-19 and respiratory failure.
Why the study?
Given the highly variable clinical phenotype of COVID-19, deeper analysis of the host genetic contribution to severe COVID-19 was needed to improve understanding of disease mechanisms.
Meta-Analysis (n=15,743)
Yes
Identified novel genetic loci, including a 17q21.31 inversion polymorphism and 19q13.33 (NAPSA), associated with severe COVID-19 respiratory failure.
No takes yet. Share an insight, caveat, or question.
Genetic risk profiling for severe COVID-19 should not yet guide clinical decisions; leaves open validation and mechanistic roles of 17q21.31 and NAPSA loci.
Degenhardt et al. (2022) conducted a meta-analysis in Severe COVID-19 (n=15,743). Host genetic variants (17q21.31 inversion polymorphism and 19q13.33 locus) vs. Population controls was evaluated on Severe COVID-19 with respiratory failure. Host genetic variants, including a ~0.9-Mb inversion polymorphism at 17q21.31 and a new locus at 19q13.33 (including NAPSA), were associated with severe COVID-19 and respiratory failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: